Arcellx and kite announce strategic collaboration to co-develop and co-commercialize late-stage clinical cart-ddbcma in multiple myeloma

-- collaboration leverages expertise across both companies, including kite's global cell therapy leadership and industry leading reliable manufacturing -- -- arcellx to receive $225m upfront payment; $100m equity investment; and up to $3.9b in total contingent consideration -- -- companies to co-commercialize and split profits in the u.s.; arcellx to receive low to mid-teen royalties outside the u.s. --   -- arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma --  -- arcellx to host a conference call and webcast today at 5:45 a.m. pt -- redwood city, calif.
ACLX Ratings Summary
ACLX Quant Ranking